Full profile
| Also known as | Panax quinquefolius, Cereboost |
|---|---|
| Best for | Acute working-memory support |
| Evidence grade | Grade C — Limited — early or small human trials |
| Studied dose range | 200 mg of standardized extract, single dose in the studied trials. |
| Time to effect | Acute — measured within 1–3 hours of a single dose. |
| Best form | Cereboost, standardized to roughly 10% ginsenosides. |
Evidence, honestly graded
Downgraded from B to C on 2026-07-11 under the house replication-over-recency + sponsor-dependence standard (the same basis used for Rhodiola and Panax). All three supporting acute trials — Scholey 2010 (PMC2952762), Ossoukhova 2015, and White 2020 (PMID 32896022, with two Naturex-employee authors) — were funded by Naturex, the Cereboost developer, and the one chronic-dosing trial (Bell 2022, doi:10.1007/s00394-021-02654-5) was largely null. A single sponsor's repeated trials are self-replication, not independent replication, so the honest grade is C. This is a different species from Asian Panax ginseng; the signals should not be read across.
See the full grading rubric — study type, replication, population match, and dose adequacy — in The Evidence Standard.
986 licensed natural health products in Health Canada's LNHPD list American Ginseng as a medicinal ingredient.
That makes American Ginseng a recognized, licensable medicinal ingredient in Canada — regulated by Health Canada's Natural and Non-prescription Health Products Directorate, which issues each licensed natural health product a Natural Product Number (NPN). Search the LNHPD to verify.
Side effects
- Generally well tolerated
Who should avoid it or check first
- On anticoagulants or antidiabetic medication without clinician review
- Pregnant or breastfeeding without clinician guidance
Interactions
- May interact with anticoagulants and antidiabetic medications — discuss with a clinician
Stacks well with
Use caution stacking with
- Panax Ginseng (redundant adaptogen mechanism without a clear rationale)
What to look for on a label
- Specify "American ginseng (Panax quinquefolius)" — not just "ginseng" — since the species and evidence base differ from Asian Panax ginseng.
- Position as acute working-memory support; chronic-use claims outrun the current evidence.
References
- Scholey 2010 — Cereboost acute working-memory RCT. Single-dose Cereboost improved working-memory measures in healthy adults. PMC2952762. Educational, not a product claim.
- Ossoukhova 2015 — American ginseng acute cognition trial. Further single-dose evidence for acute working-memory effects. PMID 25778987. Educational.
- Bell 2022 — chronic American ginseng dosing trial. Chronic daily dosing was largely null on cognitive outcomes — the honest gap between acute and chronic evidence. doi:10.1007/s00394-021-02654-5.
Grades and studied doses are our conservative reading of the human research, shown for education. They are not product claims, and a studied dose is not a recommended dose.
Revision history
Every change to this ingredient's evidence status, dated and explained. The full cross-library log lives at Evidence Updates.
- 2026-07-11Grade changeGrade B → Grade C
Downgraded from B to C. Acute cognitive effects appear in small trials but do not replicate consistently enough across doses and populations to hold a B.
See how American Ginseng compares on grade, dose, and goal in the Evidence Explorer.
